EB Report

Each month we will update you on the activities of the Executive Board of ISV.

We thank you for being a member of the International Society for Vaccines (ISV). Without you, there would be no Society. In order to enhance our communication with the members of the society, we are launching this inaugural newsletter. Each month, the newsletter will bring you information about ISV, policy updates, information about our members, points of view regarding vaccines and vaccination, as well as updates on the Annual Vaccine and ISV Congress. As President, I will use this forum to provide you feedback from our monthly Executive Board (EB) meetings and provide information about ISV and its programs. Please feel free to contact any of the Executive Board members to provide your opinion, comments, concerns, and praises about ISV. For more information on the ISV, please visit our website: http://www.isv-online.org –

–Adolfo Garcia-Sastre, ISV President

Policy Updates

The ISV Executive Board recently reviewed changes proposed by the ISV Membership Subcommittee. Membership Policies are effective immediately.

Updates to the Membership Guidelines
1. Annual calendar year for all renewals on Jan 1st.
2. A members may pay his/her membership dues via the ISV website or during the Registration process of the Vaccine and ISV Annual Congress website.
3. All members who renew or join ISV between January 1st and December 31st will have his/her membership backdated to January 1st each year.
4. If a member pays more than once in a year, the additional payments will be credited for future years.
5. Full Annual Membership will be $100 USD. Full Members will also be given the opportunity to pay $400 USD for a 5-year membership or $700 USD for a 10-year membership. Even though ISV does not currently provide or support its own independent journal, if at some point in the future a journal sub-

9th Vaccine & ISV Congress

We would like to update you on various ISV activities and fill you in on plans for the 2015 Annual ISV meeting at the 9th Global Vaccine and ISV Congress scheduled for Seoul, South Korea. More information about the meeting is provided below and will be posted on the conference website. Be sure to reserve October 17-20th on your calendar and plan to attend. We will update information on the 9th Vaccine and ISV Congress in each newsletter and on the ISV website. The 2015 meeting will follow our traditional schedule, beginning on Saturday afternoon with the pre-meeting workshops and a welcome reception. On Sunday, Monday, and Tuesday, we will have outstanding plenary and breakout sessions, as well as poster sessions. There will be time at meals and during breaks to renew and establish friendships and collaborations. Information about sightseeing and tours will be made available on our website.

–Co-Chairs Margaret Liu and Ted Ross

See remainder of update on our website.

(Continued on page 2…)
Poll of the Month

Why do you believe there has been an overall trend of increased reporting of pertussis cases since the early 1980s?

1. Increased awareness
2. Improved diagnostic tests
3. Potential changes in disease-causing bacteria strains
4. Waning immunity of acellular pertussis vaccines

Visit our website to vote!

The results are in for February 2015 monthly poll:

Do you think that the World Health Organization could have done more to reduce the ongoing Ebola outbreak in Western Africa?

- Considerably More activity would have reduced the Outbreak - 50%
- Somewhat More activity would have reduced the Outbreak - 20%
- No More activity would have reduced the Outbreak - 10%
- Unsure if any increased activity would have reduced the Outbreak - 20%

Poll of the Month selected by Leora Suprun

Paper of the Month

Current Topics in Microbiology and Immunology, 2015. [Epub ahead of print].

Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy

Click to Read

Kimberly A. Kraynyak, Angela Bodles-Brakhop and Mark Bagarazzi

Abstract: Cancer is a worldwide leading cause of death, and current conventional therapies are limited. The search for alternative preventive or therapeutic solutions is critical if we are going to improve outcomes for patients. The potential for DNA vaccines in the treatment and prevention of cancer has gained great momentum since initial findings almost 2 decades ago that revealed that genetically engineered DNA can elicit an immune response. The combination of adjuvants and an effective delivery method such as electroporation is overcoming past setbacks for naked plasmid DNA (pDNA) as a potential preventive or therapeutic approach to cancer in large animals and humans. In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance of adjuvants and electroporation with emphasis on prostate, melanoma, and cervical cancer.

Paper of the Month selected by Leora Suprun, Independent Medical Affairs Professional.

Point of View

This section will provide members each month with editorials and opinion pieces in the areas of vaccines.

“Law, Ethics, and Public Health in the Vaccination Debates”

Politics of the Measles Outbreak

Click here to read the article from Journal of the American Medical Association

ISV FELLOW OF THE MONTH

February

STANLEY A. PLOTKIN

Elected 2014, Stanley A. Plotkin, MD - Emeritus Professor of the University of Pennsylvania, USA

Click picture to read more

March

RAYMOND E. SPIER

Elected 2013, Raymond E. Spier, DPhil - Emeritus Professor of the University of Surrey, UK

Click picture to read more

ISV is now on Facebook and LinkedIn! Click the icon to visit!